Silencing the MET oncogene leads to regression of experimental tumors and metastases

Area of Science:

• Oncology
• Molecular Biology
• Cancer Genetics

Background:

• The genes driving cancer invasion and metastasis remain largely unknown, hindering effective treatment strategies.
• The MET proto-oncogene, a receptor tyrosine kinase for hepatocyte growth factor (HGF), is implicated in sensing adverse microenvironments and promoting cancer cell invasion and metastasis.
• MET overexpression, often linked to tumor hypoxia, results in its constitutive activation and is associated with poor patient prognosis.

Purpose of the Study:

• To elucidate the role of the MET oncogene in various stages of tumor progression.
• To investigate the therapeutic potential of targeting MET in established and progressing tumors.

Main Methods:

• Development of an inducible lentiviral delivery system for RNA interference (RNAi) to silence the MET gene.
• In vitro assessment of invasive growth programs following MET gene silencing.
• In vivo evaluation of tumor growth and experimental metastasis generation after MET silencing.
• Analysis of MET's role in established metastases through gene silencing.

Main Results:

• Silencing MET in overexpressing tumor cells impaired in vitro invasive growth.
• MET gene silencing led to a lack of tumor growth and reduced experimental metastasis formation in vivo.
• Targeting MET in established metastases resulted in their significant regression, indicating MET's crucial role in advanced disease.

Conclusions:

• Persistent MET oncogene expression is mandatory for cancer progression, including the maintenance of invasive and metastatic phenotypes.
• Targeting MET demonstrates therapeutic potential for inhibiting tumor growth and regression of established metastases.
• Understanding MET's function provides critical insights into cancer metastasis and potential therapeutic avenues.